Br J Cancer: Galectin-3 activates the beta-catenin signaling path line to promote liver cancer metastasis.

Hepatocellular carcinoma (HCC), one of the most common cancers, is the world's second leading cause of cancer-related death, with about 50% of cases and deaths in China.
the current treatment strategy for the disease has improved, its high metastasis also limits long-term survival.
recent studies have established anti-angiogenesic therapies for the treatment of HCC, where sorafenib has been considered a second-line treatment for non-removable or metastasis HCC.
, however, because some patients have tumor metastasis and show sorafine resistance, Solafini treatment strategies can only extend the survival of HCC patients by an average of 3 months.
, the study of the molecular mechanism of liver cancer metastasis is particularly important.
previous studies have shown that Galectin-3 (semi-lactose coagulant 3) is closely related to adverse prognostics in HCC patients.
Galectin-3 is a multi-functional protein encoded by the LGALS3 gene and belongs to the beta-semi-lactose glycoside binding protein family.
studies have shown that Galectin-3 can play an important role in tumor development in different ways, including angiogenesic, chemical resistance, immunosuppression, and tumor metastasis.
and previous studies have shown galectin-3 to be a prognostic factor in liver cancer patients, suggesting that Galectin-3 may be a key regulatory factor in the development or even metastasis of liver cancer.
the study, the researchers looked at Galectin-3's contribution to HCC transfer and the underlying molecular mechanisms of the process.
large-scale study of multiple groups of HCC patients, Galectin-3 was closely related to vascular immersion and poor survival.
Galectin-3 is involved in a variety of processes associated with tumor metastasis in HCC cells, including angiogenesic and endothion-intersecting transformation processes (EMTs).
study found that Galectin-3 activates the PI3K-Akt-GSK-3 beta-catenin signal transducting path.
IGFBP3 and waveform proteins, which are directly targeted by the beta-catenin/TCF4 transcription complex, regulate blood vessel production and EMT processes, respectively.
model studies have found that Galectin-3 enhances the development and metastasis of tumors in HCC cells through the beta-catenin signal transducting path.
addition, the absence of Galectin-3-beta-catenin signal transducting paths can work together to improve the anti-tumor effects of sorafini.
, the study found that Galectin-3-beta-catenin-IGFBP3/waveform protein signal transducting path is the main mechanism affecting HCC metastasis, providing potential biomarkers for predicting vascular metastasis and sorafinib resistance of tumors, and providing potential therapeutic targets for HCC patients.
.